ATE395923T1 - Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren - Google Patents
Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basierenInfo
- Publication number
- ATE395923T1 ATE395923T1 AT01948222T AT01948222T ATE395923T1 AT E395923 T1 ATE395923 T1 AT E395923T1 AT 01948222 T AT01948222 T AT 01948222T AT 01948222 T AT01948222 T AT 01948222T AT E395923 T1 ATE395923 T1 AT E395923T1
- Authority
- AT
- Austria
- Prior art keywords
- autoimmune
- monosacharides
- prophylactic
- infectious
- therapeutic treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20582000P | 2000-05-19 | 2000-05-19 | |
US28156701P | 2001-04-04 | 2001-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE395923T1 true ATE395923T1 (de) | 2008-06-15 |
Family
ID=26900794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01948222T ATE395923T1 (de) | 2000-05-19 | 2001-05-18 | Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren |
Country Status (21)
Country | Link |
---|---|
US (1) | US6800613B2 (de) |
EP (2) | EP1284740B1 (de) |
JP (1) | JP5004261B2 (de) |
KR (1) | KR100829674B1 (de) |
CN (1) | CN1606446A (de) |
AT (1) | ATE395923T1 (de) |
AU (3) | AU2001269695B2 (de) |
BR (1) | BR0110975A (de) |
CA (1) | CA2409221C (de) |
CY (1) | CY1108211T1 (de) |
DE (1) | DE60134134D1 (de) |
DK (1) | DK1284740T3 (de) |
ES (1) | ES2305086T3 (de) |
HU (1) | HU230847B1 (de) |
IL (3) | IL152935A0 (de) |
MX (1) | MXPA02011486A (de) |
NO (1) | NO331939B1 (de) |
NZ (1) | NZ522755A (de) |
PL (1) | PL206832B1 (de) |
PT (1) | PT1284740E (de) |
WO (1) | WO2001090129A2 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US7915238B2 (en) | 1999-02-01 | 2011-03-29 | Eisai R & D Management Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
US20040006242A1 (en) * | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US20030105032A1 (en) * | 2000-05-19 | 2003-06-05 | Persing David H. | Phophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds |
NZ531612A (en) * | 2001-09-07 | 2006-01-27 | Univ Boston | Method and composition for treating immune complex associated disorders |
EP1302206A1 (de) * | 2001-10-11 | 2003-04-16 | Universitair Medisch Centrum Utrecht | Verfahren und Mittel zur Verwendung des adventitial Toll-like-Rezeptors |
US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
EP1482955B1 (de) | 2002-02-04 | 2013-12-25 | Corixa Corporation | Prophylaktische und therapeutische behandlung von infektions- und anderen krankheiten mit immunoeffektor-verbindungen |
PL220778B1 (pl) | 2002-07-08 | 2016-01-29 | Corixa Corp | Sposoby wytwarzania 4-fosforanu aminoalkiloglukozaminidu oraz związki pośrednie |
HUE026376T2 (en) | 2003-01-06 | 2016-05-30 | Corixa Corp | Certain aminoalkyl glucosamide phosphate compounds and their use |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2005089122A2 (en) * | 2004-03-05 | 2005-09-29 | Mayo Foundation For Medical Education And Research | Animals with reduced body fat and increased bone density |
KR20070101356A (ko) * | 2005-01-27 | 2007-10-16 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 일차 낭성섬유증 결손 표적제의 효능의 특성화 방법 |
CN101355928B (zh) | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
GB0510463D0 (en) * | 2005-05-23 | 2005-06-29 | Britania Pharmaceuticals Ltd | Improvements in or relating to organic materials |
US7622128B2 (en) * | 2005-12-13 | 2009-11-24 | University Of Washington | Porphyromonas gingivalis 1435/1449 LPS as an immune modulator |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
EP2468300B1 (de) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Impfstoffzusammensetzung mit einem synthetischen Adjuvans |
US20090215710A1 (en) * | 2007-09-24 | 2009-08-27 | Reliance Life Sciences Pvt. Ltd. | Carbohydrate based toll-like receptor (tlr) antagonists |
WO2009059143A2 (en) * | 2007-10-31 | 2009-05-07 | Centocor, Inc. | Use of toll-like receptor 4 antagonists for the treatment or prevention of osteoarthritic conditions |
CN102481312B (zh) | 2009-06-05 | 2015-07-15 | 传染性疾病研究院 | 合成的吡喃葡萄糖脂佐剂 |
EP3187585A1 (de) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
DK2618842T3 (da) | 2010-09-22 | 2019-07-01 | Ena Therapeutics Pty Ltd | Hidtil ukendt immunstimulerende fremgangsmåde |
GB201101331D0 (en) | 2011-01-26 | 2011-03-09 | Glaxosmithkline Biolog Sa | Compositions and uses |
DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
US9241988B2 (en) * | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
EP3388835B1 (de) | 2012-05-16 | 2020-04-01 | Immune Design Corp. | Impfstoffe gegen hsv-2 |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
CN105188710A (zh) * | 2013-03-15 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途 |
CN105209047B (zh) | 2013-04-18 | 2020-08-18 | 免疫设计股份有限公司 | 用于癌症治疗的gla单一疗法 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
CA2942235A1 (en) | 2014-03-12 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Immunogenic liposomal formulation |
CA2942234A1 (en) | 2014-03-12 | 2015-09-17 | Glaxosmithkline Biologicals S.A. | Liposomal compositions for mucosal delivery |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
WO2017013603A1 (en) | 2015-07-21 | 2017-01-26 | Glaxosmithkline Biologicals Sa | Adjuntive immunotherapy for the prevention or treatment of infectious disease |
TW201716084A (zh) | 2015-08-06 | 2017-05-16 | 葛蘭素史克智慧財產發展有限公司 | 組合物及其用途與治療 |
RU2018107930A (ru) | 2015-08-06 | 2019-09-06 | Глэксосмитклайн Байолоджикалз Са | Агонисты tlr4, их композиции и применение для лечения рака |
WO2017021912A1 (en) | 2015-08-06 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combined tlrs modulators with anti ox40 antibodies |
AU2016362697B2 (en) | 2015-12-03 | 2018-07-12 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of STING |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | タンパク質調節物質として有用な複素環アミド |
SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
CN109328188A (zh) | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
JP2019521166A (ja) | 2016-07-20 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Perk阻害剤としてのイソキノリン誘導体 |
EP3548638A1 (de) | 2016-12-01 | 2019-10-09 | GlaxoSmithKline Intellectual Property Development Limited | Verfahren zur behandlung von krebs |
WO2018204302A1 (en) | 2017-05-01 | 2018-11-08 | Vanderbilt University | Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
EP3692033A1 (de) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulatoren des stimulators von interferongenen (sting) zur verwendung bei der behandlung von hiv |
KR20200123436A (ko) | 2018-02-12 | 2020-10-29 | 이니뮨 코퍼레이션 | 톨-유사 수용체 리간드 |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
WO2020030570A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof |
WO2020030571A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof |
WO2020031087A1 (en) | 2018-08-06 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
EP3990428A4 (de) | 2019-06-26 | 2023-07-19 | ENA Respiratory Pty Ltd | Neuartige moleküle |
BR112021025476A2 (pt) | 2019-06-26 | 2022-10-11 | Glaxosmithkline Ip Dev Ltd | Proteínas de ligação à il1rap |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
JP2022542032A (ja) | 2019-07-21 | 2022-09-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 治療用ウイルスワクチン |
WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
WO2021048081A1 (en) | 2019-09-09 | 2021-03-18 | Glaxosmithkline Biologicals Sa | Immunotherapeutic compositions |
CA3155173A1 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
CN112999233B (zh) * | 2019-12-19 | 2023-10-20 | 中国医学科学院药物研究所 | 一类来源于赤芍的单萜苷类化合物及其制法和应用 |
WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
US20240002425A1 (en) * | 2020-11-11 | 2024-01-04 | Daiichi Sankyo Company, Limited | Novel aminoalkyl glucosaminide 4-phosphate derivative |
EP4032547A1 (de) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce abgeleitete fragemente zur hsv therapie |
EP4301733A1 (de) | 2021-03-02 | 2024-01-10 | GlaxoSmithKline Intellectual Property Development Limited | Substituierte pyridine als dnmt1-inhibitoren |
WO2022208353A1 (en) | 2021-03-31 | 2022-10-06 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US4844894A (en) | 1984-07-12 | 1989-07-04 | Ribi Immunochem Research Inc. | Method of inhibiting the onset of septicemia and endotoxemia |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
EP0324455A3 (de) * | 1988-01-15 | 1991-03-27 | Hans O. Ribi | Neue polymerische Immuno-Adjuvans |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
EP0487587A1 (de) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern |
AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) * | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) * | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6368604B1 (en) * | 1997-09-26 | 2002-04-09 | University Of Maryland Biotechnology Institute | Non-pyrogenic derivatives of lipid A |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
PL354714A1 (en) | 1998-04-09 | 2004-02-09 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
KR100586804B1 (ko) * | 1998-07-14 | 2006-06-07 | 와이어쓰 홀딩스 코포레이션 | 모노포스포릴 지질 에이를 함유하는 보조제 및 백신 조성물 |
US6013640A (en) | 1998-08-21 | 2000-01-11 | Ribi Immunochem Research, Inc. | Phosphoglycolipid and methods for its use |
US6261573B1 (en) * | 1998-10-30 | 2001-07-17 | Avant Immunotherapeutics, Inc. | Immunoadjuvants |
CA2348928C (en) * | 1998-11-03 | 2010-01-26 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn,Volksgezondheid En Cultuur | Lps with reduced toxicity from genetically modified gram negative bacteria |
WO2001010221A1 (en) | 1999-08-06 | 2001-02-15 | Corixa Corporation | Vaccines for the treatment of autoimmune disease |
WO2001034794A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Biologicals S.A. | Casb7434, an antigen over-expressed in colon cancer |
US6699846B2 (en) * | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
-
2001
- 2001-05-18 EP EP01948222A patent/EP1284740B1/de not_active Expired - Lifetime
- 2001-05-18 ES ES01948222T patent/ES2305086T3/es not_active Expired - Lifetime
- 2001-05-18 CA CA2409221A patent/CA2409221C/en not_active Expired - Lifetime
- 2001-05-18 PT PT01948222T patent/PT1284740E/pt unknown
- 2001-05-18 NZ NZ522755A patent/NZ522755A/en not_active IP Right Cessation
- 2001-05-18 PL PL365169A patent/PL206832B1/pl not_active IP Right Cessation
- 2001-05-18 KR KR1020027015626A patent/KR100829674B1/ko active IP Right Grant
- 2001-05-18 WO PCT/US2001/016327 patent/WO2001090129A2/en active Application Filing
- 2001-05-18 BR BR0110975-8A patent/BR0110975A/pt not_active IP Right Cessation
- 2001-05-18 HU HU0301815A patent/HU230847B1/hu unknown
- 2001-05-18 DE DE60134134T patent/DE60134134D1/de not_active Expired - Lifetime
- 2001-05-18 AU AU2001269695A patent/AU2001269695B2/en not_active Expired
- 2001-05-18 US US09/861,466 patent/US6800613B2/en not_active Expired - Lifetime
- 2001-05-18 AT AT01948222T patent/ATE395923T1/de active
- 2001-05-18 IL IL15293501A patent/IL152935A0/xx unknown
- 2001-05-18 MX MXPA02011486A patent/MXPA02011486A/es active IP Right Grant
- 2001-05-18 EP EP08153476A patent/EP2000144A1/de not_active Withdrawn
- 2001-05-18 JP JP2001586316A patent/JP5004261B2/ja not_active Expired - Lifetime
- 2001-05-18 DK DK01948222T patent/DK1284740T3/da active
- 2001-05-18 AU AU6969501A patent/AU6969501A/xx active Pending
- 2001-05-18 CN CNA018114881A patent/CN1606446A/zh active Pending
-
2002
- 2002-11-19 NO NO20025543A patent/NO331939B1/no not_active IP Right Cessation
- 2002-11-19 IL IL152935A patent/IL152935A/en unknown
-
2007
- 2007-05-11 AU AU2007202117A patent/AU2007202117B2/en not_active Expired
- 2007-10-08 IL IL186495A patent/IL186495A/en active IP Right Grant
-
2008
- 2008-07-24 CY CY20081100772T patent/CY1108211T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE395923T1 (de) | Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren | |
ATE342728T1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
DE122009000075I1 (de) | Methoden und zusammensetzungen für die behandlung von glomerulonephritis | |
DE69535349D1 (de) | Implantierbare aktive medizinische Vorrichtung mit Mittel zur Unterscheidung zwischen Ruhe- bzw. Aktivzustand des Patienten | |
DE69116380D1 (de) | Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit | |
DE69530844D1 (de) | Verfahren und substanzen gegen protozoen | |
DE69835536D1 (de) | Zusammensetzungen zur behandlung von staphylococcus aureus infektionen | |
ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
DE69631381T2 (de) | Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen | |
DE69603635T2 (de) | Katheterstruktur für medizinische Behandlung | |
DE69825605D1 (de) | Behandlung der schizophrenie und der psychose | |
ATE357912T1 (de) | Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten | |
DE69927380D1 (de) | Oxazolidinones zur behandlung von augeninfektionen | |
ATE213163T1 (de) | Verfahren zur behandlung von motorischen defiziten | |
DE69303234D1 (de) | Behandlung von entzündlichen Darmerkrankungen | |
DE60112768D1 (de) | Behandlung von entzündlichen erkrankungen | |
ES2180750T3 (es) | Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena. | |
DE60040555D1 (de) | Küle | |
NO984198L (no) | FremgangsmÕte for behandling av aggresjon | |
UA31764A (uk) | Спосіб лікування холедохолітіазу | |
DE60037195D1 (de) | Verbindungen zur behandlung von infektionskrankheiten und störungen des immunsystems sowie methoden ihrer anwendung | |
HUP0002639A2 (hu) | Eljárás a vastagbél bakteriális fertőzéséből eredő betegségek kezelésére | |
ATE337745T1 (de) | Behandlungsinstrument für die medizinische oder zahnmedizinische behandlung von kindern | |
RU2000107857A (ru) | Способ лечения мыта лошадей | |
ATE276760T1 (de) | Verfahren zur herstellung von autovakzinen zur behandlung von chlamydiosen von säugetieren und menschen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1284740 Country of ref document: EP |